/APRE
APRE Stock - Aprea Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.93+2.19%
+$0.02 (+2.19%) • Dec 19
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APRE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.92 – $0.94
TARGET (TP)$1.07
STOP LOSS$0.86
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.57
52W High$5.00
52W Low$0.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.50M | $583,231 | N/A | N/A | N/A |
| Gross Profit | $-7,860,956 | $576,179 | $-16,402,273 | $-271,677 | $-229,610 |
| Gross Margin | -523.2% | 98.8% | N/A | N/A | N/A |
| Operating Income | $-14,319,655 | $-15,471,963 | $-113,392,228 | $-37,446,353 | $-52,811,212 |
| Net Income | $-12,958,711 | $-14,286,756 | $-112,662,027 | $-36,536,576 | $-53,916,802 |
| Net Margin | -862.4% | -2449.6% | N/A | N/A | N/A |
| EPS | $-2.35 | $-3.95 | $-1359.79 | $-34.88 | $-50.61 |
Company Overview
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
APREBeat Rate
68%
Last 19 quarters
Avg Surprise
-12.2%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-0.47
Q4 2025
EPS Surprise History
Q1 24
-64.3%
$-0.92vs$-0.56
Q2 24
+14.1%
$-0.67vs$-0.78
Q3 24
+9.4%
$-0.58vs$-0.64
Q4 24
+14.7%
$-0.64vs$-0.75
Q1 25
+29.0%
$-0.49vs$-0.69
Q2 25
-0.9%
$-0.66vs$-0.65
Q3 25
+31.2%
$-0.53vs$-0.77
Q4 25
-327.3%
$-0.47vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.11 | $-0.47 | -327.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.77 | $-0.53 | +31.2% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.65 | $-0.66 | -0.9% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.69 | $-0.49 | +29.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.75 | $-0.64 | +14.7% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.64 | $-0.58 | +9.4% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.78 | $-0.67 | +14.1% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-0.56 | $-0.92 | -64.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.08 | $-0.86 | +20.4% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.43 | $-0.87 | +39.2% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-1.51 | $-1.34 | +11.3% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-2.60 | $-0.92 | +64.6% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-5.60 | $-2.40 | +57.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-7.60 | $-19.80 | -160.5% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-7.60 | $-7.20 | +5.3% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-8.80 | $-7.20 | +18.2% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-8.80 | $-9.00 | -2.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-9.40 | $-9.60 | -2.1% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-10.40 | $-9.20 | +11.5% | ✓ BEAT |
Latest News
Aprea Therapeutics Files For Resale Of 5.5M Share By Selling Stockholders
📉 NegativeBenzinga•Dec 19, 2025, 09:17 PM
Aprea Therapeutics Updates 2025 Progress, Cash Runway To Support Operations Through Q1 2027
📈 PositiveBenzinga•Dec 18, 2025, 01:39 PM
Aprea Therapeutics Enters $3.1M Securities Purchase Agreement Through Sale Of 2,623,023 Shares And Warrants At A Combined Price Of $1.165
➖ NeutralBenzinga•Dec 9, 2025, 01:38 PM
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate, Sales $1.848K Down From $354.621K YoY
📉 NegativeBenzinga•Nov 12, 2025, 01:42 PM
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 01:40 PM
Aprea To Feature Preliminary Results From ACESOT-1051 Trial Through September 17 In Poster Presentation At AACR-NCI-EORTC
➖ NeutralBenzinga•Oct 24, 2025, 12:35 PM
Aprea Therapeutics Determines RP2D Of 1,100 Mg Once Daily For ATRN-119, Oral ATR Inhibitor In Monotherapy Arm Of Ongoing ABOYA-119 Phase 1/2a Dose-Escalation Study, In Patients With Advanced Solid Tumors.
📈 PositiveBenzinga•Oct 15, 2025, 12:04 PM
Aprea Therapeutics Announces Two Abstracts On Clinical Programs, APR-1051 And ATRN-119, Accepted For Poster Presentation At EORTC-NCI-AACR International Conference
📈 PositiveBenzinga•Oct 14, 2025, 12:03 PM
Frequently Asked Questions about APRE
What is APRE's current stock price?
Aprea Therapeutics, Inc. (APRE) is currently trading at $0.93 per share. The stock has moved +2.19% today.
What is the analyst price target for APRE?
No analyst price targets are currently available for this stock.
What sector is Aprea Therapeutics, Inc. in?
Aprea Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is APRE's market cap?
Aprea Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does APRE pay dividends?
No, Aprea Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
ADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
Explore stocks similar to APRE for comparison